↓ Skip to main content

Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer

Overview of attention for article published in British Journal of Cancer, March 2015
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (84th percentile)
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

news
1 news outlet
patent
1 patent

Citations

dimensions_citation
46 Dimensions

Readers on

mendeley
84 Mendeley
citeulike
1 CiteULike
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer
Published in
British Journal of Cancer, March 2015
DOI 10.1038/bjc.2015.74
Pubmed ID
Authors

K L Mahon, H-M Lin, L Castillo, B Y Lee, M Lee-Ng, M D Chatfield, K Chiam, S N Breit, D A Brown, M P Molloy, G M Marx, N Pavlakis, M J Boyer, M R Stockler, R J Daly, S M Henshall, L G Horvath

Abstract

Docetaxel improves symptoms and survival in metastatic castration-resistant prostate cancer (CRPC). However, ∼50% of patients are chemoresistant. This study examined whether changes in cytokine levels predict for docetaxel resistance in vitro and in a clinical cohort. PC3 cells or their docetaxel-resistant subline (PC3Rx) were co-cultured with U937 monocytes, with and without docetaxel treatment, and cytokine levels were measured. The circulating levels of 28 cytokines were measured pre-/post cycle 1 of docetaxel from 55 men with CRPC, and compared with prostate-specific antigen (PSA) response. PC3Rx-U937 co-culture expressed more cytokines, chiefly markers of alternative macrophage differentiation, compared with PC3-U937 co-culture. Docetaxel treatment enhanced cytokine production by PC3Rx-U937 co-culture, while reducing cytokine levels in PC3-U937. In patients, changes in the levels of seven circulating cytokines (macrophage inhibitory cytokine 1 (MIC1), interleukin (IL)-1ra, IL-1β, IL-4, IL-6, IL-12 and IFNγ) after cycle 1 of docetaxel were associated with progressive disease (all P<0.05). The combination of changes in MIC1, IL-4 and IL-6 most strongly predicted PSA response (P=0.002). In vitro studies suggest docetaxel resistance is mediated, at least in part, by cytokines induced by the interaction between the docetaxel-resistant tumour cells and macrophages. Early changes in circulating cytokine levels were associated with docetaxel resistance in CRPC patients. When considered together, these data suggest a significant role for the inflammatory response and macrophages in the development of docetaxel resistance in CRPC.British Journal of Cancer advance online publication, 31 March 2015; doi:10.1038/bjc.2015.74 www.bjcancer.com.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 84 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 1%
Unknown 83 99%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 20 24%
Researcher 17 20%
Student > Bachelor 11 13%
Student > Doctoral Student 8 10%
Student > Master 7 8%
Other 13 15%
Unknown 8 10%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 18 21%
Medicine and Dentistry 17 20%
Agricultural and Biological Sciences 14 17%
Pharmacology, Toxicology and Pharmaceutical Science 4 5%
Nursing and Health Professions 3 4%
Other 15 18%
Unknown 13 15%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 March 2023.
All research outputs
#3,062,763
of 23,524,722 outputs
Outputs from British Journal of Cancer
#1,897
of 10,584 outputs
Outputs of similar age
#40,527
of 266,062 outputs
Outputs of similar age from British Journal of Cancer
#79
of 132 outputs
Altmetric has tracked 23,524,722 research outputs across all sources so far. Compared to these this one has done well and is in the 86th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 10,584 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.7. This one has done well, scoring higher than 81% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 266,062 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 84% of its contemporaries.
We're also able to compare this research output to 132 others from the same source and published within six weeks on either side of this one. This one is in the 34th percentile – i.e., 34% of its contemporaries scored the same or lower than it.